Compound useful for the treatment of degenerative and inflammatory diseases
US-9707237-B2 · Jul 18, 2017 · US
Novel compound useful for the treatment of degenerative and inflammatory diseases
US2018000831A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018000831-A1 |
| Application number | US-201715651116-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 17, 2017 |
| Priority date | Jun 26, 2009 |
| Publication date | Jan 4, 2018 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
First claim
Opening claim text (preview).
1 . A compound according to Formula I: or a pharmaceutically acceptable salt thereof. 2 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according claim 1 . 3 . The pharmaceutical composition according to claim 2 comprising a further therapeutic agent. 4 . (canceled) 5 . (canceled) 6 . (canceled) 7 . (canceled) 8 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a compound of claim 1 , sufficient to effect said treatment, prevention or prophylaxis. 9 . The method according to claim 8 , wherein the said compound is administered in combination with a further therapeutic agent. 10 . The pharmaceutical composition according to claim 2 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. 11 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment, prevention or prophylaxis. 12 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a pharmaceutical composition of claim 3 , sufficient to effect said treatment, prevention or prophylaxis. 13 . The method according to claim 11 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent. 14 . The method according to claim 12 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent. 15 . The method according to claim 9 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. 16 . The method according to claim 13 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. 17 . The method according to claim 14 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. 18 . The method according to claim 8 , wherein the inflammatory condition is rheumatoid arthritis. 19 . The method according to claim 11 , wherein the inflammatory condition is rheumatoid arthritis. 20 . The method according to claim 12 , wherein the inflammatory condition is rheumatoid arthritis.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antineoplastic agents · CPC title
specific for metastasis · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2018000831A1 cover?
- A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartil…
- Who is the assignee on this patent?
- Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jan 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).